India emerging infectious disease diagnostics market to hit USD 982.7M

The “India emerging infectious disease diagnostics market: Focus on epidemiology, application, technology, type of infection, disease type, and end user – Analysis and forecast, 2023-2033” report has been added to ResearchAndMarkets.com’s offering.

The India emerging infectious disease diagnostics market is set for substantial growth over the forecast period from 2023 to 2033. In 2022, the market was estimated to be valued at $339.1 million, and it is expected to reach a remarkable $982.7 million by 2033, demonstrating a notable CAGR of 10.29% during the forecast period.

Market lifecycle stage
The India emerging infectious disease diagnostics market is currently in an emerging phase. Recent advancements in diagnostic technologies, especially with the emergence of next-generation sequencing and the increased demand for rapid testing due to events like the Covid-19 pandemic, have contributed to the market’s development. Innovations and technologies that offer quicker, more efficient, or cost-effective diagnostic solutions could further propel the market into a growth phase.

Industry impact
The India emerging infectious disease diagnostics market plays a pivotal role in modern biotechnology, clinical diagnostics, and pathogen research. Its impact on healthcare and public health is significant:

Accurate and Timely Diagnosis: Infectious disease diagnostics enable precise identification of causative agents, leading to timely and appropriate treatment. Early diagnosis improves patient outcomes, reduces morbidity and mortality rates, and curtails the spread of infectious diseases.

Effective Patient Management: Diagnostic tests provide essential information for healthcare providers to guide patient management. They aid in selecting the most effective treatment options, including the appropriate use of antimicrobial therapies and the implementation of infection control measures, resulting in enhanced patient care and healthcare outcomes.

Public Health Surveillance and Outbreak Control: Infectious disease diagnostics are critical for public health surveillance. They identify and monitor infectious agents, aiding in the detection and tracking of disease outbreaks. This data helps public health authorities implement timely interventions such as contact tracing, isolation measures, and targeted vaccination campaigns to control infection spread.

Research and Development: Infectious disease diagnostics drive research and development efforts to enhance existing diagnostic methods and create new technologies. Ongoing advancements in diagnostics contribute to the discovery of novel biomarkers, improved diagnostic accuracy and sensitivity, and the integration of innovative approaches like molecular techniques, biosensors, and artificial intelligence.

Some of the prominent companies in this market are:

• Abbott Laboratories
• Becton, Dickinson and Company
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Co-Diagnostics, Inc.
• DANAHER CORPORATION
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG

Research and Markets